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skeptic to true believer
Steven Dickman
For most people, the trip from the
Whitehead Institute at MIT (the
Massachusetts Institute of
Technology) to Harvard Medical
School is a two-mile bus ride. For
Richard Mulligan, who late last year
became the first director of the
Harvard Gene Therapy Initiative, it
seems like a voyage to a new world.
It is daunting enough that
Mulligan had to move from the
MIT’s ‘research is all that counts’
atmosphere to the ‘it wouldn’t hurt to
wear a tie’ corridors of Harvard
Medical School and its affiliated
hospitals, which are joint sponsors of
the initiative. But for Mulligan, who
appeared tieless for an interview at an
upscale Cambridge restaurant, the
move represents an even greater leap
— from skeptic about gene therapy to
true believer. As a founder member
of the RAC — the Recombinant
DNA Advisory Committee set up to
screen gene therapy protocols for the
US National Institutes of Health
(NIH) — Mulligan became known as
a nitpicking critic of what he saw as
premature attempts to conduct
human studies of scientifically
dubious genetic therapies. He was
seen as wanting to have it both ways,
saying yes to basic research but no to
clinical trials. In his new post, he has
assumed responsibility for actually
making gene therapy work in humans.
Mulligan earned his reputation by
developing and testing some of the
earliest and most successful vector
systems for delivering genes to
experimental animals. Shaped by his
undergraduate years at MIT and 15
years on the faculty there, Mulligan
admits he was a purist about most of
the applications that poured in to the
RAC. At MIT, he had been trained to
critically evaluate data, without
allowing any implications of the
findings to bias his interpretation. By
contrast, he says “some people
interpreted their scientific data poorly
in order to go forward in the clinic.”
Some of gene therapy’s early
advocates were clinicians who
criticized Mulligan for his hesitation.
He remembers them arguing that
they had patients dying and needed
to move ahead despite not having all
the facts. Mulligan also raised some
colleagues’ ire by warning that
shoddy gene therapy experiments
would soil the field.
Now, a decade later, Mulligan’s
skepticism has been validated at the
highest possible level. A 1995 report
by an influential NIH-appointed
committee slammed prior gene
therapy trials as unsuccessful and
“oversold,” filled with experiments
that suffered from weak design and
non-informative outcomes. Worse
yet, despite a NIH gene therapy
budget of $200 million a year, the
report found that there had been a
“very low frequency of gene transfer”
and that in more than 100 protocols,
not a single patient had been
definitively helped. Consequently,
the report called for a return to basic
laboratory science rather than long-
shot studies of patients.
“I could have written that report
myself five years earlier,” says
Mulligan, who by then was on
sabbatical at Somatix, a California
biotechnology company he had
helped to found. His stint in biotech
also confirmed that there was a lot of
basic research still to be done before
the field would be ready for
companies to kick in with the
developmental phase. Mulligan’s own
laboratory work, which he continued
even while working at the company,
never strayed from a fundamental
rule: “If gene therapy were banned
tomorrow, would our science be of
intrinsic interest?”
At the same time, even as the
clinical failures piled up, Mulligan’s
confidence grew that someday
human gene therapy would succeed
— and that the field would proceed
without him if he did not find a way
to become active in moving the basic
science discoveries into the clinic.
It would have been easy enough
to stay on at Somatix. “They were
beginning to work on cancer
vaccines, which I had been very
interested in,” he recalls, “. . . and
they were beginning to succeed,” at
least in certain systems. But making
gene therapy work at a company is
complicated by the fact that even
successful techniques may not be
applicable to large enough patient
groups to be profitable, says MIT
molecular biologist and Nobel
laureate Phillip Sharp, one of
Mulligan’s mentors. On top of that,
adds Sharp, “In the long term,
Richard would never fit in at a
company — he’s too free-spirited.”
Meanwhile, Harvard beckoned,
beginning with an offer to move his
laboratory to the Harvard-affiliated
Children’s Hospital. Mulligan would
also become a well funded Howard
Hughes Medical Institute
investigator in making the move.
But the recruitment effort went
beyond the Children’s Hospital and
the Howard Hughes. All the Harvard-
affiliated hospitals and the Dean of
the Medical School itself, Daniel
Tosteson, agreed that Harvard needed
an initiative in gene therapy. One of
the recruiters told Mulligan that it was
the first thing all the hospitals could
agree on in about 50 years. All in all,
Mulligan got the impression that
Harvard Medical School could
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become something it never had been
before — a hotbed of gene therapy
research. It was a remarkable
opportunity. Mulligan was offered one
laboratory at the Children’s Hospital
to work on the basic science of viral
vectors, and a second laboratory in a
central Harvard building that will
manufacture the vectors for use in
human trials.
Despite all these enticements,
Mulligan did not agree to move —
and leave a position at the
Whitehead that he fondly recalls as
“the best job in the world” — until
he became convinced that his
Harvard colleagues were skeptics
too. “There was long-term optimism
mixed with scientific conservatism,”
the ideal mix. “I didn’t have to
cheapen my way of doing things.”
In Mulligan’s view, he himself
and Harvard are not the only
beneficiaries. The fact that Harvard
is taking an active role in gene
therapy will also increase the chances
that gene therapy will be better
sooner. Because of Harvard’s
conservatism, it will not repeat the
mistakes of others and rush into
human trials without a long-term
plan for each disease it studies.
Furthermore, Harvard provides an
academic, rather than a corporate
setting for the work. These days,
major researchers in basic science
fields have so many industry
affiliations that it often makes it
difficult for them to work with each
other. Mulligan believes Harvard
offers an unusual opportunity to bring
the best minds together. “It’s exactly
the sort of environment needed for
the basic research that will drive the
development of gene therapies.”
For Mulligan, says hematologist
Stuart Orkin of the Children’s
Hospital, the Harvard offer
presented a very simple choice:
either make gene therapy work
yourself or stop criticizing it. “In
other words, put up or shut up,” says
Orkin. “This is putting up.”
Steven Dickman is a freelance science writer
based in Cambridge, Massachusetts.
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The Novartis
Foundation
What is it famous for? The name isn’t
well-known yet. For now, it’s
probably best described as ‘the
scientific charity formerly known as
The Ciba Foundation’.
Why the change of name? The Ciba
parent company no longer exists. It
merged with that other
pharmaceuticals giant Sandoz in
December 1996 to form a new
company, Novartis. In response, the
Foundation adopted the name of its
new benefactor on 1 September 1997.
When was it founded? Robert Käppeli,
managing director of the Ciba
company of Basel, Switzerland,
persuaded the company to form a
charitable Trust in 1947, to promote
international cooperation in medical,
chemical and biological research. He
pushed strongly for it to be located in
London, partly because English was
already becoming the international
language of science, but also because
the laws under which UK-based
charities operate would ensure
complete independence for the
Foundation, and he insisted the two
should have no commercial ties. (Also,
being Swiss, he had presumably
considered the fact that charities in
the UK get considerable tax breaks.)
Where is the Foundation? It took a
while to find a suitable site in the
bomb-damaged centre of London,
but Ciba restored a fine building in
Portland Place, near Regent’s Park,
and the doors were opened in 1949.
Because the neighbourhood is thick
with embassy staff and private
medical practitioners from nearby
Harley Street, there is a prevalence
of suits and flashy cars not familiar to
most scientists outside the Howard
Hughes Medical Institute.
What does the Foundation do? It is
best known for its Symposia — held
eight times a year — and in the UK
for its efforts to bridge the gap
between scientists and the media. It
also provides a very central and
affordable hotel service at Portland
Place, used by those few visiting
scientists in the know.
How do I get to a Symposium? You
don’t, unless you’re already a force to
be reckoned with in your field, or one
of the few Foundation bursars. The
emphasis is on relaxed and intimate
discussion, so groups are limited to 25
invited guests. Unlike the situation at
many other meetings, the ‘audience’
are at least as eminent as the
‘speakers’, and there is slightly more
time set aside for discussion than for
talks — so it’s not simply a case of a
few hurried questions before coffee.
Topics must be interdisciplinary, and
the aim is to select burgeoning fields
that will become hot within about the
next year. In an effort to reach a wider
audience without sacrificing the cosy
atmosphere of the meetings, the
proceedings are recorded and
published almost verbatim.
How does it promote science elsewhere?
The Foundation maintains a
database of leading experts in
science, medicine and technology —
the Media Resource Service —
which European journalists can use
to contact an expert in any given
field (from asteroids to BSE). It also
organizes a public debate at the
British Association for the
Advancement of Science Annual
Science Festival — this year, on
cross-species organ transplantation.
How is it financed? The Foundation
has always been funded on an annual
basis by a donation from the founder
company — £1.3 million in 1996. So
far, the donations have remained
fairly consistent, being tied to the
needs of the Foundation, rather than
to the fortunes of the company. It
remains to be seen whether anything
will change apart from the name.
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